Fibronectin-Targeting MRI Contrast Agent for Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cancer imaging techniques lack target-specific contrast agents for accurate early diagnosis of malignant tumors, and existing contrast agents often provide limited functionality due to insufficient sensitivity and concentration, leading to inaccurate or misleading MR images.
Innovation Solution
Development of targeted MRI contrast agents with specific binding affinity for fibronectin and its complexes, comprising cyclic or linear peptides covalently attached to chelating agents and metal ions, which enhance contrast and relaxivity in imaging cancer-related biomarkers and tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional contrast agents are used, then imaging can be performed, but the spatial resolution and diagnostic accuracy are limited
Solution Approach 1:
The contrast agent is designed with a fibronectin-targeting peptide sequence (CREKA or CLT1) that provides local specificity to tumor tissues. This local quality enhancement allows the agent to accumulate preferentially in malignant tumors through binding to fibronectin, thereby improving both spatial resolution and diagnostic accuracy simultaneously.
Solution Approach 2:
The contrast agent combines multiple functional components: a fibronectin-targeting peptide (CREKA or CLT1), a chelating agent (DOTA), and a paramagnetic metal ion (Gd3+). This composite structure integrates targeting capability, contrast enhancement, and magnetic relaxation properties to achieve superior imaging performance.
2Measurement precision
If conventional contrast agents are used, then imaging can be performed, but the sensitivity and concentration are insufficient
Solution Approach 1:
The fibronectin-targeting peptide sequence enables the contrast agent to accumulate locally in tumor tissues with high specificity. This local accumulation mechanism significantly enhances sensitivity by concentrating the contrast agent where it is needed, rather than distributing it uniformly throughout the body.
Solution Approach 2:
The peptide sequence CREKA or CLT1 is designed to mimic and bind to the fibronectin protein structure found in tumor extracellular matrices. This molecular copying approach allows the contrast agent to exploit the natural binding sites of fibronectin for targeted accumulation.
3Reliability
If conventional contrast agents are used, then imaging can be performed, but the signal changes are not observed
Solution Approach 1:
The contrast agent utilizes the paramagnetic properties of Gd3+ ions to significantly alter MRI signal parameters (T1 and T2 relaxation times). This parameter change approach ensures that signal changes are clearly observable and detectable, improving both reliability and measurement precision of the imaging results.
Solution Approach 2:
The composite structure combining Gd3+ ions with the fibronectin-targeting peptide and DOTA chelator creates a contrast agent that simultaneously provides strong magnetic signal enhancement and specific tissue targeting, ensuring observable and accurate signal changes.
4Reliability
If conventional contrast agents are used, then imaging can be performed, but the results may be inaccurate or misleading
Solution Approach 1:
By confining the contrast agent to tumor tissues through fibronectin-specific binding, the agent eliminates background interference and provides localized diagnostic information. This local quality enhancement prevents misleading results by ensuring the signal reflects only the target tissue characteristics.
Solution Approach 2:
The peptide sequence is designed to specifically copy and bind to fibronectin, a marker protein found in tumor extracellular matrices. This specific molecular recognition ensures that the imaging results accurately reflect tumor presence and characteristics without false positives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted contrast agents significantly improve the detection of atherosclerotic plaques and tumors by enhancing MR image contrast and relaxivity, allowing for more accurate and early diagnosis of maladies, while minimizing spurious background signals.
Implementation Method 1
the contrast agent must interfere with the wavelength of electromagnetic radiation used in the imaging technique, alter the physical properties of tissue to yield an altered signal
Implementation Method 2
imaging agents that have specific binding affinity for fibronectin and its complexes with fibrin or collagen. The imaging agents have a cyclic peptide covalently attached to an imaging agent... comprising cyclic or linear peptides covalently attached to chelating agents and metal ions
Data Source
AI summary
Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.